The latest round of warning letters from the U.S. Food and Drug Administration (FDA) include a dairy company cited for inaccurate nutritional claims, two seafood processors for inadequate HACCP plans, and three cattle producers for excessive drug treatments. FDA found that Minerva Dairy in Minerva, OH, misbranded its Greek yogurt butter product labels by including inaccurate nutrient claims. The labels claim that the product is useful in maintaining healthy dietary practices, but its nutritional content does not meet requirements to make such a claim, FDA stated. San Jose, CA-based seafood processor Il Pastaio Inc. was found to have serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulations. FDA found that the firm did not have a HACCP plan for its frozen seafood ravioli products to control against the food safety hazards of pathogens, potential toxin formation, and undeclared allergens. Another seafood producer, Prospect Enterprises in Los Angeles, CA, was also found to have violated the HACCP regulations for failing to provide evidence that its imported seafood products were processed under conditions equivalent to those required of domestic producers. Mills Dairy Farm in Perrysville, OH, sold an animal for slaughter that was deemed adulterated for excessive levels of the drug florfenicol in the muscle, FDA stated. While the agency has established a tolerance of 0.3 parts per million of florfenicol in muscle, the sample from Mills Dairy Farm contained 3.62 ppm in the muscle. The farm was also cited for inadequate record-keeping of drug treatments. Cattle producer Rex L. Jessee of New Tazewell, TN, was cited for excessive levels of a drug, sulfamethazine. An animal sold by Jessee was found to have 0.229 ppm of the drug in its liver, more than twice the legal tolerance of 0.1 ppm. Jessee was also cited for inadequate record-keeping of drug treatments. Finally, FDA stated that Stoney Hill Farms of Saltsburg, PA, sold a bob veal calf for slaughter that tested for nearly three times the legal limit in its tissues of the drug dihydrostreptomycin. Stoney Hill was also cited for inadequate record-keeping of drug treatments. Each company was given 15 days to respond to the concerns raised by FDA in the warning letters.